Quanta Appoints Hooman Hakami as Non-Executive Director
22 July 2020: Quanta Dialysis Technologies Ltd, a British medical technology innovation company, today announces the appointment of Hooman Hakami to the Company’s Board as an independent Non-Executive Director, with immediate effect.
Hooman has 30 years of leadership experience, including senior positions at two of the world’s largest medical devices companies. At Medtronic, he was Executive Vice President and President of the Diabetes Group and prior to that he spent more than 20 years at General Electric, where he was a Company Officer.
Johan de Ruiter, Chairman of the board said, “I am very pleased to welcome Hooman to the Quanta Board. His commercial experience in introducing disruptive technologies will be a large asset to the Company as we continue with the rollout and preparation of US market launch of SC+, Quanta’s small, simple and versatile haemodialysis system. I look forward to working with Hooman as we expand production of SC+ over the coming months, improving the lives of haemodialysis patients”.
It is a pleasure to join the Quanta Board. Kidney failure is a growing clinical issue, but the way it has been treated hasn’t fundamentally changed in almost 20 years. As we have seen with the COVID-19 crisis, patients need and want remote, point-of-care solutions. Quanta’s haemodialysis technology and its elegant SC+ system have been designed with this in mind. Because the system is engineered for freedom it is extremely well positioned to drive a transformation in kidney failure management. I look forward to working with the Board and the senior leadership team to achieve the full potential of SC+ and help improve the lives of as many patients as possible.